NVDA
NVIDIA
-- 138.850 GRAB
Grab Holdings
-- 4.900 TSLA
Tesla
-- 355.840 INTC
Intel
-- 23.600 BABA
Alibaba
-- 124.730 
Despite Hybio Pharmaceutical's share price surge, its high P...
Despite Hybio Pharmaceutical's share price surge, its high P/S ratio and declining medium-term revenue could risk shareholders' investments. If the P/S aligns with recent negative growth rates, investors may face disappointment.
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28%
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4831
Followers
0
Following
11K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call